Cargando…

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells

The xCT light chain of the cystine/glutamate transporter (system X(C)(−)) is of importance for the survival of triple-negative breast cancer (TNBC) cells. The MUC1-C transmembrane oncoprotein is aberrantly overexpressed in TNBC and, like xCT, has been linked to maintaining glutathione (GSH) levels a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Masanori, Takahashi, Hidekazu, Rajabi, Hasan, Alam, Maroof, Suzuki, Yozo, Yin, Li, Tagde, Ashujit, Maeda, Takahiro, Hiraki, Masayuki, Sukhatme, Vikas P., Kufe, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914246/ https://www.ncbi.nlm.nih.gov/pubmed/26930718 http://dx.doi.org/10.18632/oncotarget.7598

Ejemplares similares

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma
por: Tagde, Ashujit, et al.
Publicado: (2017)

DNA METHYLATION BY DNMT1 AND DNMT3b METHYLTRANSFERASES IS DRIVEN BY THE MUC1-C ONCOPROTEIN IN HUMAN CARCINOMA CELLS
por: Rajabi, Hasan, et al.
Publicado: (2016)

MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia
por: Tagde, Ashujit, et al.
Publicado: (2016)

MUC1-C drives DNA methylation in cancer
por: Rajabi, Hasan, et al.
Publicado: (2016)

MUC1-C ACTIVATES BMI1 IN HUMAN CANCER CELLS
por: Hiraki, Masayuki, et al.
Publicado: (2016)

MUC1-C ACTIVATES THE TAK1 INFLAMMATORY PATHWAY IN COLON CANCER
por: Takahashi, Hidekazu, et al.
Publicado: (2015)

MUC1-C activates EZH2 expression and function in human cancer cells
por: Rajabi, Hasan, et al.
Publicado: (2017)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

MUC1-C INTEGRATES PD-L1 INDUCTION WITH REPRESSION OF IMMUNE EFFECTORS IN NON-SMALL CELL LUNG CANCER
por: Bouillez, Audrey, et al.
Publicado: (2017)

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
por: Hiraki, Masayuki, et al.
Publicado: (2018)

Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells
por: Alam, Maroof, et al.
Publicado: (2014)

Increased expression of cystine/glutamate antiporter in multiple sclerosis
por: Pampliega, Olatz, et al.
Publicado: (2011)

Change of cystine/glutamate antiporter expression in ethanol-dependent rats
por: Peana, Alessandra T., et al.
Publicado: (2014)

Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues
por: Martis, Renita M., et al.
Publicado: (2020)

The System xc- Cystine/Glutamate Antiporter: An Exciting Target for Antiepileptogenic Therapy?
por: Gallagher, Martin
Publicado: (2020)

MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors
por: Hiraki, Masayuki, et al.
Publicado: (2016)

Corticostriatal dysfunction and social interaction deficits in mice lacking the cystine/glutamate antiporter
por: Bentea, Eduard, et al.
Publicado: (2020)

Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment
por: Hung, Chung-Chieh, et al.
Publicado: (2021)

Molecular basis for redox control by the human cystine/glutamate antiporter system xc(−)
por: Parker, Joanne L., et al.
Publicado: (2021)

Early Onset of Age-Related Cataracts in Cystine/Glutamate Antiporter Knockout Mice
por: Martis, Renita Maria, et al.
Publicado: (2021)

MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells
por: Kosugi, Michio, et al.
Publicado: (2011)

High-Throughput Assay Development for Cystine-Glutamate Antiporter (x(c) (-)) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells
por: Thomas, Ajit G., et al.
Publicado: (2015)

The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility
por: Shin, Chun-Shik, et al.
Publicado: (2017)

Cystine/glutamate antiporter System x(c)(-) deficiency impairs insulin secretion in mice
por: de Baat, Axel, et al.
Publicado: (2023)

TARGETING THE eIF4A RNA HELICASE BLOCKS TRANSLATION OF THE MUC1-C ONCOPROTEIN
por: Jin, Caining, et al.
Publicado: (2012)

COOPERATIVITY OF THE MUC1 ONCOPROTEIN AND STAT1 PATHWAY IN POOR PROGNOSIS HUMAN BREAST CANCER
por: Khodarev, Nikolai, et al.
Publicado: (2009)

Implication of the glutamate–cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis
por: Fournier, M., et al.
Publicado: (2017)

Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury
por: Meyer, Anne R., et al.
Publicado: (2019)

The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
por: Jyotsana, Nidhi, et al.
Publicado: (2022)

Cystine/Glutamate Antiporter and Aripiprazole Compensate NMDA Antagonist-Induced Dysfunction of Thalamocortical L-Glutamatergic Transmission
por: Fukuyama, Kouji, et al.
Publicado: (2018)

Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
por: Arensman, Michael D., et al.
Publicado: (2019)

Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: Evidence of ferroptosis
por: Ashraf, Azhaar, et al.
Publicado: (2020)

Cystine/Glutamate antiporter system x(c)(-) deficiency impairs macrophage glutathione metabolism and cytokine production
por: de Baat, Axel, et al.
Publicado: (2023)

The cystine/glutamate antiporter system x(c)(−) drives breast tumor cell glutamate release and cancer-induced bone pain
por: Slosky, Lauren M., et al.
Publicado: (2016)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

The x(c)(−) cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
por: Lo, M, et al.
Publicado: (2008)

Analysis of DNA methylation associates the cystine–glutamate antiporter SLC7A11 with risk of Parkinson’s disease
por: Vallerga, Costanza L., et al.
Publicado: (2020)

Cooperative Interaction between the MUC1-C Oncoprotein and the Rab31 GTPase in Estrogen Receptor-Positive Breast Cancer Cells
por: Jin, Caining, et al.
Publicado: (2012)

MUC1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism
por: Stroopinsky, Dina, et al.
Publicado: (2018)

Cystine–glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice
por: Sprimont, Lindsay, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a6ellppij94gka2mndp9mhmlel